AnaptysBio (ANAB) Stock Price Down 10.7%

AnaptysBio Inc (NASDAQ:ANAB)’s share price fell 10.7% during trading on Friday . The stock traded as low as $68.04 and last traded at $72.33. 836,519 shares changed hands during trading, an increase of 126% from the average session volume of 369,494 shares. The stock had previously closed at $81.04.

Several brokerages have commented on ANAB. Zacks Investment Research downgraded AnaptysBio from a “hold” rating to a “sell” rating in a report on Friday. Cantor Fitzgerald set a $140.00 price target on AnaptysBio and gave the company a “buy” rating in a report on Friday. Credit Suisse Group set a $143.00 price target on AnaptysBio and gave the company a “buy” rating in a report on Friday. Royal Bank of Canada reiterated a “hold” rating and set a $84.00 price target on shares of AnaptysBio in a report on Wednesday, August 8th. Finally, JMP Securities lowered their price target on AnaptysBio from $180.00 to $153.00 and set a “buy” rating on the stock in a report on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. AnaptysBio presently has an average rating of “Buy” and a consensus target price of $130.50.

The company has a debt-to-equity ratio of 0.01, a current ratio of 16.19 and a quick ratio of 16.19. The firm has a market cap of $1.93 billion, a P/E ratio of -47.59 and a beta of 3.47.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.05. The company had revenue of $5.00 million for the quarter. On average, equities research analysts expect that AnaptysBio Inc will post -2.72 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. boosted its position in shares of AnaptysBio by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 84,342 shares of the biotechnology company’s stock valued at $5,992,000 after acquiring an additional 5,067 shares during the period. Quantitative Systematic Strategies LLC bought a new stake in shares of AnaptysBio in the second quarter valued at approximately $211,000. Brown Advisory Inc. boosted its position in shares of AnaptysBio by 1.5% in the second quarter. Brown Advisory Inc. now owns 102,114 shares of the biotechnology company’s stock valued at $7,253,000 after acquiring an additional 1,500 shares during the period. BlackRock Inc. boosted its position in shares of AnaptysBio by 2.9% in the second quarter. BlackRock Inc. now owns 1,464,624 shares of the biotechnology company’s stock valued at $104,046,000 after acquiring an additional 41,507 shares during the period. Finally, Sei Investments Co. bought a new stake in shares of AnaptysBio in the second quarter valued at approximately $780,000.

TRADEMARK VIOLATION NOTICE: This article was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.wkrb13.com/2018/11/10/anaptysbio-anab-stock-price-down-10-7.html.

About AnaptysBio (NASDAQ:ANAB)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Featured Story: Google Finance Portfolio

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply